This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Cystic Fibrosis
and you are
over 6
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

Oral supplementation of patients affected by cystic fibrosis with docosahexanoic acid (DHA) will result in normalization of the known fatty acid derangements in these patients and will diminish the production of proinflammatory isoprostanes such as 8-isoprostane-PGF2α.

Provided treatments

  • : Docosahexanoic Acid Supplement
  • : Placebo
Tris trial is registered with FDA with number: NCT00924547. The sponsor of the trial is Vanderbilt University and it is looking for 17 volunteers for the current phase.
Official trial title:
Oral Docosahexanoic Acid Supplementation in Cystic Fibrosis: Effects on Exhaled Pro-inflammatory Isoprostanes and Analysis of Its Esterification Sites in Plasma